View Item 

Show simple item record

Epothilones and the next generation of phase III trials for prostate cancer
dc.contributor.authorBhandari, Manish S.en_US
dc.contributor.authorHussain, Maha H. A.en_US
dc.date.accessioned2010-06-01T18:20:02Z
dc.date.available2010-06-01T18:20:02Z
dc.date.issued2005-08en_US
dc.identifier.citationBhandari, Manish S.; Hussain, Maha (2005). "Epothilones and the next generation of phase III trials for prostate cancer." BJU International 96(3): 296-302. <http://hdl.handle.net/2027.42/71543>en_US
dc.identifier.issn1464-4096en_US
dc.identifier.issn1464-410Xen_US
dc.identifier.urihttps://hdl.handle.net/2027.42/71543
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16042717&dopt=citationen_US
dc.format.extent174166 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Science Ltden_US
dc.rights2005 BJU INTERNATIONALen_US
dc.subject.otherEpothilonesen_US
dc.subject.otherChemotherapyen_US
dc.subject.otherHormone-refractory Prostate Canceren_US
dc.titleEpothilones and the next generation of phase III trials for prostate canceren_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialtiesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationum* Division of Hematology Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USAen_US
dc.identifier.pmid16042717en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/71543/1/j.1464-410X.2005.05618.x.pdf
dc.identifier.doi10.1111/j.1464-410X.2005.05618.xen_US
dc.identifier.sourceBJU Internationalen_US
dc.identifier.citedreferenceJemal A, Murray T, Ward E et al. Cancer statistics 2005. CA Cancer J Clin 2005; 55: 10 – 30en_US
dc.identifier.citedreferenceHan M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001; 28: 555en_US
dc.identifier.citedreferenceCoen JJ, Zietman AL, Thakral H, Shipley WU. Radical radiation for localized prostate cancer. local persistence of disease results in a late wave of metastases. J Clin Oncol 2002; 20: 3199en_US
dc.identifier.citedreferenceCarroll PR, Kantoff PW, Balk SP et al. Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. Urology 2002; 60 ( Suppl ): 1en_US
dc.identifier.citedreferenceChodak GW, Keane T, Klotz L. Critical evaluation of hormonal therapy for carcinoma of the prostate. Urology 2002; 60: 201en_US
dc.identifier.citedreferenceKelly Wm, Scher HI. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol 1993; 149: 607en_US
dc.identifier.citedreferenceHarris KA, Weinberg V, Bok RA, Kakefuda M, Small E J. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer. J Urol 2002; 168: 542en_US
dc.identifier.citedreferenceSmall EJ, Vogelzang NJ. Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J Clin Oncol, 1997; 15: 382en_US
dc.identifier.citedreferencePetrylak DP, Tangen C, Hussain M et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513 – 20en_US
dc.identifier.citedreferenceTannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502 – 12en_US
dc.identifier.citedreferenceBhandari MS, Petrylak DP, Hussain M. Clinical trials in metastatic prostate cancer – has there been real progress in the past decade? Eur J Cancer 2005; 41: 941 – 53en_US
dc.identifier.citedreferenceBollag DM, McQueney PA, Zhu J et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 1995; 55: 2325 – 33en_US
dc.identifier.citedreferenceGerth K, Bedorf N, Hofle G et al. Epothilons A and B. Antifungal and cytotoxic compounds from Sorangium cellulosum ( Myxobacteria ): Production, physico-chemical and biological properties. J Antibiot (Tokyo) 1996; 49: 560 – 3en_US
dc.identifier.citedreferenceLee FY, Borzilleri R, Fairchild CR et al. BMS-247550. a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 2001; 7: 1429 – 37en_US
dc.identifier.citedreferenceGoodin S, Kane MP, Rubin EH. Epothilones. mechanism of action and biological activity. J Clin Oncol 2004; 22: 2015 – 25en_US
dc.identifier.citedreferenceHorwitz SB. Mechanism of action of taxol. Trends Pharmacol Sci 1992; 13: 134 – 6en_US
dc.identifier.citedreferenceJordan MA, Toso RJ, Thrower D et al. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 1993; 90: 9552 – 6en_US
dc.identifier.citedreferenceTrielli MO, Andreassen PR, Lacroix FB et al. Differential Taxol-dependent arrest of transformed and nontransformed cells in the G1 phase of the cell cycle, and specific-related mortality of transformed cells. J Cell Biol 1996; 135: 689 – 700en_US
dc.identifier.citedreferenceWahl AF, Donaldson KL, Fairchild C et al. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nature Med 1996; 2: 72 – 9en_US
dc.identifier.citedreferenceBelotti D, Vergani V, Drudis T et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 1996; 2: 1843 – 9en_US
dc.identifier.citedreferenceKowalski RJ, Giannakakou P, Hamel E. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol). J Biol Chem 1997; 272: 2534 – 41en_US
dc.identifier.citedreferenceNogales E, Wolf SG, Khan IA et al. Structure of tubulin at 6.5 A and location of the taxol-binding site. Nature 1995; 375: 424 – 7en_US
dc.identifier.citedreferenceBode CJ, Gupta ML Jr, Reiff EA et al. Epothilone and paclitaxel: Unexpected differences in promoting the assembly and stabilization of yeast microtubules. Biochemistry 2002; 41: 3870 – 4en_US
dc.identifier.citedreferenceGiannakakou P, Gussio R, Nogales E et al. A common pharmacophore for epothilone and taxanes: Molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci USA 2000; 97: 2904 – 9en_US
dc.identifier.citedreferenceVerrills NM, Flemming CL, Liu M et al. Microtubule alterations and mutations induced by desoxyepothilone B. Implications for drug–target interactions. Chem Biol 2003; 10: 597 – 607en_US
dc.identifier.citedreferenceWartmann M, Altmann K-H. The biology and medicinal chemistry of epothilones. Curr Med Chem Anti-Canc Agents 2002; 2: 123 – 48en_US
dc.identifier.citedreferenceHussain M, Faulkner J, Vaishampayan U et al. Epithilone B, (Epo-B) analogue BMS-247550a (NSC 710428) administered every 21 days in patients (pts) with hormone refractory prostate cancer (HRPC). A Southwest Oncology Group Study (S0111). Program and Abstracts of the 40th Annual Meeting of the American Society of Clinical Oncology; June 5–8, 2004. New Orleans, Louisiana. Abstract 4510en_US
dc.identifier.citedreferenceKelly WK, Galsky MD, Small EJ et al. Multi-institutional trial of the epothilone B analogue BMS-247550 with or without estramustine phosphate (EMP) in patients with progressive castrate-metastatic prostate cancer (PCMPC): Updated results. Program and Abstracts of the 40th Annual Meeting of the American Society of Clinical Oncology; June 5–8, 2004; New Orleans, Louisiana. Abstract 4509en_US
dc.identifier.citedreferenceRosenberg JE, Galsky MD, Weinberg V et al. Response to second-line taxane-based therapy after first-line epothilone B analogue BMS 247550 (BMS) therapy in hormone refractory prostate cancer. Abstracts of the ASCO Prostate Cancer Symposium; February 17–19, 2005; Orlando, Florida. Abstract 267en_US
dc.identifier.citedreferenceVanteenkiste JF, Breton JL, Sandler A et al. A randomized phase II study of epothilone analog BMS-247550 in patients with non-small cell lung cancer who have failed first-line platinum-based chemotherapy. Proc Am Soc Clin Oncol 2003; 22: 626en_US
dc.identifier.citedreferenceMekhail T, Chung C, Holden S et al. Phase I trial of novel epothilone B analog BMS-310705 IV q21 days. Proc Am Soc Clin Oncol 2003; 22: 129, A515en_US
dc.identifier.citedreferenceSessa C, Perotti A, Malossi A et al. Phase I and pharmacokinetic study of the novel epothilone BMS-310705 in patients with advanced solid cancer. Proc Am Soc Clin Oncol 2003; 22: 130, A519en_US
dc.identifier.citedreferenceWartmann M, Koppler, J, Larigot M et al. Epothilones A and B accumulate several-hundred fold inside cells. Proc Am Soc Cancer Res 2000; 41: 213, A1362en_US
dc.identifier.citedreferenceHussain A, Dipaola RS, Baron AD et al. A, Phase I. trial of weekly EPO906 in patients with hormone-refractory prostate cancer (HRPC). Program and Abstracts of the 40th Annual Meeting of the American Society of Clinical Oncology; June 5–8, 2004; New Orleans, Louisiana. Abstract 4563en_US
dc.identifier.citedreferenceNelson J, Bagnato A, Battistini B, Nisen P. The endothelin axis: emerging role in cancer. Nat Rev Cancer 2003; 3: 110 – 6en_US
dc.identifier.citedreferenceNelson JB, Lee WH, Nguyen SH et al. Methylation of the 5′ CpG island of the endothelin B receptor gene is common in human prostate cancer. Cancer Res 1997; 57: 35 – 7en_US
dc.identifier.citedreferenceMundy GR, Yin JJ, Mohammad KS et al. A. Endothelin-1 and osteoblastic metastasis. Proc Natl Acad Sci USA 2003; 100: 10588 – 9en_US
dc.identifier.citedreferenceYin JJ, Mohammad KS, Kakonen SM et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci USA 2003; 100: 10954 – 9en_US
dc.identifier.citedreferenceNelson JB, Chan-Tack K, Hedican SP et al. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res 1996; 56: 663 – 8en_US
dc.identifier.citedreferencePapandreou CN, Usmani B, Geng Y et al. Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nature Med 1998; 4: 50 – 7en_US
dc.identifier.citedreferenceNelson JB, Hedican SP, George DJ et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nature Med 1995; 1: 944 – 9en_US
dc.identifier.citedreferencePao MM, Tsutsumi M, Liang G, Uzvolgyi E, Gonzales FA, Jones P. A. The endothelin receptor B (EDNRB) promoter displays heterogeneous, site specific methylation patterns in normal and tumor cells. Hum Mol Genet 2001; 10: 903 – 10en_US
dc.identifier.citedreferenceJeronimo C, Henrique R, Campos PF et al. Endothelin B receptor gene hypermethylation in prostate adenocarcinoma. J Clin Pathol 2003; 56: 52 – 5en_US
dc.identifier.citedreferenceWessale JL, Adler AL, Novosad EI et al. Pharmacology of endothelin receptor antagonists ABT-627, ABT-546, A-182086 and A-192621: ex vivo and in vivo studies. Clin Sci (Lond) 2002; 103 ( Suppl. 48 ): 112S – 117Sen_US
dc.identifier.citedreferencePirtskhalaishvili G, Nelson JB. Endothelium-derived factors as paracrine mediators of prostate cancer progression. Prostate 2000; 44: 77 – 87en_US
dc.identifier.citedreferenceFizazi K, Yang J, Peleg S et al. Prostate cancer cells–osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clin Cancer Res 2003; 9: 2587 – 97en_US
dc.identifier.citedreferenceCarducci MA, Padley RJ, Breul J et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003; 21: 679 – 89en_US
dc.identifier.citedreferenceCarducci M, Nelson JB, Saad F et al. Effects of atrasentan on disease progression and biological markers in men with metastatic hormone-refractory prostate cancer: phase 3 study. Proc Am Soc Clin Oncol 2004; 23: 396, A4508en_US
dc.identifier.citedreferenceNelson JB. Endothelin receptor antagonists. World J Urol 2005; 23: 19 – 27en_US
dc.identifier.citedreferenceRosano L, Spinella F, Salani D et al. Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma. Cancer Res 2003; 63: 2447 – 53en_US
dc.identifier.citedreferenceDel Bufalo D, Di Castro V, Biroccio A et al. Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: requirement for Akt activation. Mol Pharmacol 2002; 61: 524 – 32en_US
dc.identifier.citedreferenceLara PN Jr, Twardowski P, Quinn DI. Angiogenesis-targeted therapies in prostate cancer. Clin Prostate Cancer 2004; 3: 165 – 73en_US
dc.identifier.citedreferencePicus J, Halabi S, Rini BI et al. The use of bevacizumab (B) with docetaxel (D) and estramustine (E) in hormone refractory prostate cancer (HRPC): initial results of CALGB 90006. Proc Am Soc Clin Oncol 2004; 22: 1578Aen_US
dc.identifier.citedreferenceHalabi S, Small EJ, Kantoff PW et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003; 21: 1232 – 7en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1464-410X.2005.05618.x.pdf
Size:
170.0KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.